Cardiomyocytes Derived from Human Cardiopoietic Amniotic Fluids

Angela Di Baldassarre1, Maria A D’Amico1, Pascal Izzicupo1, Giulia Gaggi1, Simone Guarnieri2, Maria A Mariggiò2, Ivana Antonucci3, Barbara Corneo4, Dario Sirabella4, Liborio Stuppia2 & Barbara Ghinassi1

Human amniotic fluid (hAF) cells share characteristics of both embryonic and adult stem cells. They proliferate rapidly and can differentiate into cells of all embryonic germ layers but do not form teratomas. Embryoid-bodies obtained from hAF have cardiac differentiation potential, but terminal differentiation to cardiomyocytes (CMs) has not yet been described. Our purpose was to promote cardiac differentiation in hAF-cells. Cells were exposed to inducing factors for up to 15 days. Only the subset of hAF cells expressing the multipotency markers SSEA4, OCT4 and CD90 (Cardiopoietic AF cells) responded to the differentiation process by increasing the expression of the cardiac transcription factors Nkx2.5 and GATA4, sarcomeric proteins (cTnT, α-MHC, α-SA), Connexin43 and atrial and ventricular markers. Furthermore, differentiated cells were positive for the calcium pumps CACNA1C and SERCA2a, with approximately 30% of Cardiopoietic AF-derived CM-like cells responding to caffeine or adrenergic stimulation. Some spontaneous rare beating foci were also observed. In conclusion, we demonstrated that Cardiopoietic AF cells might differentiate toward the cardiac lineage giving rise to CM-like cells characterized by several cardiac-specific molecular, structural, and functional properties.

Cardiovascular (CV) diseases are the main cause of mortality in the industrialized world, with an estimated 17.7 million deaths by CV in 2015, representing 31% of all global deaths1. Therefore, studies on CV biology, disease modeling, drug discovery and regenerative medicine represent a priority and an unmet medical need2,3. The prospect of repairing an injured heart with cells that can be cultured and expanded ex vivo and then functionally integrated upon transplantation is appealing. Moreover, the availability of in vitro human models of cardiac disorders reflecting human disease phenotypes has become crucial for the discovery and development of therapeutics. Indeed, much of our knowledge on the molecular pathways leading to human CV disorders has been derived from animal models4–5, but considerable differences exist between human and mouse genomes, and species-specific physiological properties lead to considerable functional differences6–7. To generate stem cell models of human CV disease and foster advances in regenerative medicine, it is critical to be able to generate and expand human CV progenitors or terminally differentiated, functional cardiac cells. Different types of stem cells have already been shown to have cardiomyogenic potential8–9. For example, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells can be differentiated into beating cells with a cardiac-like phenotype in vitro. iPS cells are patient specific and may be used to avoid the immunological and ethical concerns of ES cells10–11, but their clinical use may be tempered by their tumorigenic potential12. Despite these encouraging premises, a safe source of cardiomyocytes (CMs) or CM progenitor cells to use for cell replacement therapy of damaged cardiac muscle tissue is still not available.

Mid-trimester human amniotic fluid (hAF) cells are a heterogeneous population that includes stem cells with intermediate features between embryonic and adult stem cells: indeed, they are characterized by a high proliferation rate, the expression of both pluripotent and mesenchymal markers and the ability to differentiate into lineages representative of all three germ layers, while maintaining the non-tumor-forming properties of adult cells13. Previous studies have already demonstrated that hAF cells express several cardiac-associated genes and that these cells can be induced along the cardiac lineage by modulating WNT signaling or by exposure to demethylating agents14–16. Nonetheless, it is well established that this differentiation process occurs with a very low yield. Hence,

1Department of Medicine and Aging Sciences, University “G. d’Annunzio” of Chieti-Pescara, Via dei Vestini 31, 66100, Chieti, Italy. 2Department of Neuroscience, Imaging e Clinical Sciences, University “G. d’Annunzio” of Chieti-Pescara, Via dei Vestini 31, 66100, Chieti, Italy. 3Department of Psychological, Humanities and Territorial Sciences, University “G. d’Annunzio” of Chieti-Pescara, Via dei Vestini 31, 66100, Chieti, Italy. 4Stem Cell Core Facility, Columbia University Medical Center, 650W. 168th St., 10032, New York, NY, USA. Correspondence and requests for materials should be addressed to B.G. (email: b.ghinassi@unich.it)
enabling high-throughput cardiogenesis in hAF cells has obvious therapeutic potential. However, hAF contains diverse cellular subpopulations. The percentage of cells expressing pluripotency markers varies greatly among reports from different labs. For example, while several groups used CD117 (c-Kit, type III tyrosine kinase receptor for stem cell factor) to isolate the undifferentiated population, other authors failed to select CD117+ cells from hAFs in undifferentiated conditions.

The aim of this study was to dissect and promote the cardiomyogenic potential of hAF cells to obtain differentiated progenies with morphological and functional features of CM. For this purpose, 15 hAF samples were analyzed for the expression of embryonic markers and then induced to cardiac differentiation through two different protocols: one based on Embryoid Body (EB) formation and the other in which cell monolayers were sequentially exposed to known cardiac differentiation inducers.

Results
Phenotypical characterization of hAF samples. hAFs, isolated as previously described, were characterized by flow cytometry between passages 6 and 8. As in previous studies, we demonstrated that they expressed the mesenchymal stem cell markers CD29, CD73 and CD44, whereas they were negative for the hematopoietic markers CD34 and CD45 and for the endothelial marker PECAM-1/CD31. On the other hand, positivity for the expression of the pluripotent stem cell markers SSEA4, OCT4, Tra-1–60 and CD90 was extremely variable among samples (Table 1 and Supplemental Table 1).

Samples with a pluripotency profile give rise to EBs with cardiac differentiation potential. It has already been described that hAF cells, such as ESCs, can give rise to EBs, three-dimensional aggregates representing one of the hallmarks of pluripotent stem cells and an optimal starting point for in vitro lineage-specific differentiation. When we tested the different samples for their ability to form EBs, we obtained three-dimensional aggregates only from the AF samples in which cells expressed SSEA4, OCT4 and CD90 but not from the samples expressing one of the hematopoietic markers CD34 and CD45 and for the endothelial marker PECAM-1/CD31. On the other hand, positivity for the expression of the pluripotent stem cell markers SSEA4, OCT4, Tra-1–60 and CD90 was extremely variable among samples (Table 1 and Supplemental Table 1).

| AF Sample | Age at pregnancy (yr) | Time of Amniocentesis (Watts of Gestation) | Fetal Karyotype | SSEA4 (AF cells) | OCT4 (AF cells) | CD90 (AF cells) | EBs formation |
|-----------|----------------------|-------------------------------------------|----------------|-----------------|----------------|----------------|---------------|
| #1        | 38                   | 16                                        | 46, XY         | 65.3            | 60.2           | 84.1           | +             |
| #2        | 38                   | 16                                        | 46, XY         | 9.8             | 13.5           | 30.1           | –             |
| #3        | 37                   | 16                                        | 46, XY         | 9.9             | 3.8            | 9.1            | –             |
| #4        | 38                   | 16                                        | 46, XY         | 54.5            | 15.4           | 93.5           | +             |
| #5        | 40                   | 16                                        | 46, XY         | 82.2            | 73.7           | 48.1           | +             |
| #6        | 40                   | 17                                        | 46, XY         | n.d.            | 9.9            | n.d.           | –             |
| #7        | 42                   | 16                                        | 46, XY         | 5.7             | 6.7            | 43.3           | –             |
| #8        | 41                   | 16                                        | 46, XY         | 6.3             | 2.4            | 10.2           | –             |
| #9        | 39                   | 16                                        | 46, XY         | 80.4            | 12.5           | 64.6           | +             |
| #10       | 35                   | 17                                        | 46, XY         | 59.1            | 78.5           | 45.6           | +             |
| #11       | 41                   | 16                                        | 46, XY         | 25.1            | n.d.           | 7.8            | –             |
| #12       | 38                   | 16                                        | 46, XY         | 9.9             | 6.8            | 51.3           | –             |
| #13       | 38                   | 16                                        | 46, XY         | 6.8             | 7.4            | 5.7            | –             |
| #14       | 32                   | 17                                        | 46, XY         | 63.9            | 12.1           | 90.0           | +             |
| #15       | 35                   | 17                                        | 46, XY         | 56.8            | 82.7           | 81.1           | +             |

Table 1. Characterization of AF cells samples. In bold are highlighted the AF cells samples (Cardiopoietic AF cells) able to give rise to EB-like aggregates. n.d.: not detectable.
underwent all the steps of the differentiation protocol. The expression of “early” and “late” cardiac-specific proteins was then analyzed by Western blot, flow cytometry and immunofluorescence microscopy.

**Induction of cardiac differentiation affects the expression and localization of the cardiac nuclear factors GATA4 and Nkx2.5 in Cardiopoietic AF cells.** The expression of the “early” cardiac markers GATA4 and Nkx2.5 was monitored during the different phases of the differentiation protocol (Fig. 2). Flow cytometry, Western blot and immunofluorescence showed that the exposure of Cardiopoietic AF cells to BMP4 and activin A induced a dramatic increase in GATA4 and Nkx2.5 expression, mainly at the cytoplasmic level. After myocardial induction by VEGF, cells still overexpressed these nuclear factors, but microscopic observation documented their massive translocation into the nuclei. After 15 days of differentiation, GATA4 and Nkx2.5 were still highly expressed, even though they were mainly confined in the cytoplasm.

**Structural and functional cardiac protein expression after differentiation.** After 15 days of culture in the differentiation conditions described above, Cardiopoietic AF cells changed their morphology, becoming more elongated (cell size: 39.5 ± 8.4 × 12.65 ± 3.4 μm vs 97.24 ± 34.25 × 9.6 ± 5.6 μm before and after differentiation, respectively, p < 0.05). We then analyzed these cells for the expression of specific “late” cardiac markers, such as sarcomeric proteins and Cx43. Interestingly, differentiated cells expressed high levels of cTnT, α-MHC and α-SA (Table 2 and Fig. 3); in some cells, α-SA displayed typical sarcomeric striations. Additionally, the expression of Cx43, which weakly marked the cytoplasm of undifferentiated Cardiopoietic AF cells, dramatically increased after differentiation and moved to the cell periphery, suggesting a specific localization of this protein at the membrane level (Table 2 and Fig. 3).

We also observed by Western blot, flow cytometry and immunofluorescence the dramatic induction of the CACNA1C and SERCA2 proteins, two calcium pumps involved in excitation/contraction coupling that reside in the sarcotenda. In Cardiopoietic AF cells and SERCA2 immunolabeling changed from diffuse cytoplasmic dots in Cardiopoietic AF cells into reticulated organization that resembled the sarcoplasmic reticulum (Fig. 4c). Beyond the expression of calcium pumps CACNA1C and SERCA2, we evidenced by Western blot that Cardiopoietic AF derived CM-like cells expressed also other voltage gated ion channels that are central in the cardiac action potential: in particular, we detected the presence of the Na(+) channel Nav1.5 that is involved in the initiation and conduction of action potentials, the “delayed rectifier” potassium channel KCNQ1 which is required for repolarization phase of the cardiac action potential, and

---

**Figure 1.** Analysis of the cardiac potential of Cardiopoietic AF cell-derived EBs. Representative ImageStream images of Cardiopoietic AF and Cardiopoietic AF cell-derived EB cells labeled with anti-CD90 (fuchsia)/anti-Nkx2.5 (green) (a) and with anti-CD90 (fuchsia)/anti-α-MHC (green) (b). Nuclei were counterstained with Syto16 (blue). Bars: 10 μm. (c) % of CD90+, Nkx2.5+, nuclear Nkx2.5+ and α-MHC+ cells are expressed as the mean ± SD. *indicates values significantly different from Cardiopoietic AF. Data are representative of seven independent experiments.
inward-rectifier potassium ion channel Kir2.1 that contributes to phase 3 repolarization and plays a major role in setting the resting membrane potential of CMs (Fig. 4b).

Finally, to better characterize the nature of the CM-like cells obtained from Cardiopoietic AF cells cultured in a monolayer, we verified the expression of atrial myosin light chain 7 (MYL7) and the ventricular-specific transcription factor iroquois homeobox 4 (IRX4). Western blot, flow cytometry and immunofluorescence showed that cardiac differentiation resulted in the upregulation of both of these proteins (Fig. 5 and Table 2); in particular, while the ventricular marker showed only a slight, albeit significant, upregulation, we observed a dramatic increase in the expression of the atrial marker MYL7. The morphological study demonstrated that the contractile protein MYL7 localized in the cytoplasm of the differentiated cells, where the signal was organized in longitudinal fibers; the transcription factor IRX4, on the other hand, was confined to the nuclei of the positive cells (Fig. 5c).

Table 2. Cell Positivity (%) of Cardiopoietic AF cells before and after differentiation. Data are expressed as the mean ± SD *p < 0.05 relative to Cardiopoietic AF cells.

| Protein | Cardiopoietic AF cells (%) | CMs (%) |
|---------|---------------------------|--------|
| α-MHC  | 0.9 ± 0.5                 | 89.6 ± 8.1* |
| α-SA   | 4.5 ± 3.7                 | 84.7 ± 9.7* |
| cTnT   | 3.1 ± 2.5                 | 84.9 ± 10.1* |
| Cx43   | 42.8 ± 10.8               | 81.5 ± 10.2* |
| CACNA1C| 15.7 ± 9.3                | 85.8 ± 9.8* |
| SERCA2 | 46.6 ± 12.8               | 84.1 ± 11.5* |
| RYR    | 1.2 ± 1.2                 | 25.1 ± 6.6* |
| MYL7   | 0.5 ± 0.3                 | 65.7 ± 11.3* |
| IRX4   | 0.4 ± 0.5                 | 15.1 ± 4.4* |

Figure 2. Cytometric and immunofluorescent analyses of the expression and localization of the early cardiac markers GATA4 and Nkx2.5 during the different phases of the differentiation protocol. Cardiopoietic AF: before the differentiation process; mesodermal induction: after 24 hrs of activin A and BMP4; myocardial induction: after 72 hrs of VEGF; cardiomyocytes: after 15 days of differentiation. (a) Flow cytometry histograms: gray line, isotype control; blue line, Cardiopoietic AF; green line, mesodermal induction; yellow line, myocardial induction; red line, cardiomyocytes obtained after 15 days of differentiation. (b) % of positive cells and mean fluorescence intensity at each differentiation step. Data are expressed as the mean ± SD. (c) Immunofluorescent staining for GATA4 (green), Nkx2.5 (red) and nuclei (blue) during the different phases of the differentiation protocol. The bottom line shows the merged fluorescence, as indicated. Scale bar: 10 μm. Data are representative of seven independent experiments.
CM-like cells generated from Cardiopoietic AF cells may present spontaneous beating foci and show functional characteristics of immature CMs. Although after differentiation, the majority of cells expressed large amounts of sarcomeric proteins and some specific proteins involved in cardiac excitation/contraction coupling, foci of spontaneous contraction were only rarely observed (Supplementary Video S1). We then investigated the physiological properties of the CM-like cells generated from Cardiopoietic AF cells. First, using fluorescence video imaging, we demonstrated that approximately 30% of the cells presented spontaneous intracellular \( \text{Ca}^{2+} \) waves (Fig. 6a, Supplementary Video S2). Then, we verified whether the cardiopoietic AF–derived CM-like cells displayed cardiac features of the excitation-contraction mechanism. Cells were stimulated with 50 mM KCl, a depolarizing agent that allows the calcium entry into the cells by the activation of the L-type \( \text{Ca}^{2+} \) channels present on the sarcolemma. In the presence of external \( \text{Ca}^{2+} \), approximately 35% of cells showed an intracellular \( \text{Ca}^{2+} \) increase; this response was not observed when, as a control, cells were stimulated in the absence of extracellular \( \text{Ca}^{2+} \). We then checked for the presence and activity of the Ryanodine receptors (RyRs), channels essential to cardiac contraction because they mediate the outflow of calcium ions from the sarcoplasmic reticulum. Flow cytometry analysis of CM-like cells generated from Cardiopoietic AF cells showed that 25% of cells expressed RyRs (Fig. 6c). To test the maturity of these calcium channels, cells were stimulated with 40 mM caffeine, an RyR agonist. After treatment, approximately 20% of cells bathed in \( \text{Ca}^{2+} \)-free medium responded by increasing intracellular \( \text{Ca}^{2+} \) (Fig. 6b). These data suggested that when expressed, RyRs were also active and responsive to specific agonists.

We next sought to determine whether \( \beta \)-adrenergic signaling, a canonical CM signaling pathway, was operational in Cardiopoietic AF cell-derived CM-like cells. Western blot analysis demonstrated that differentiation was accompanied by increased expression of \( \beta_1 \)-AR, while \( \beta_2 \)-AR was weakly or not modulated (Fig. 6d). When we tested the responsiveness of the cells to isoproterenol, a nonselective \( \beta \)-adrenergic receptor agonist that enhances \( \text{Ca}^{2+} \) influx by phosphorylating L-type \( \text{Ca}^{2+} \) channels, we observed a weak potentiation in the KCl-evoked intracellular \( \text{Ca}^{2+} \) increase in approximately 10% of cells (Fig. 6e). These results suggest that \( \beta \)-adrenergic receptors and their associated intracellular signaling partners are present and functional only in a portion of CM-like cells derived from Cardiopoietic AF cell samples.

**Discussion**

The ideal goal of stem cell therapy is to substitute necrotic or dysfunctional cardiac tissue with new competent CMs derived from stem cells. To date, the only source that has given unambiguous results about cardiogenic potential are ES23–25 and iPS cells11,23,26,27, but ethical barriers and clinical concerns have hampered their use in the medical context28. hAF cells could circumvent these limits and provide effective cell replacement therapy for cardiac diseases, particularly for application to congenital heart defect repair14,18. Here, we characterized a...
population named Cardiopoietic AF cells, with a profile of pluripotency that may give rise to a cell population that displays morphological and functional features of CMs.

We previously demonstrated that unselected second trimester AFs may form EBs expressing stem cells specific genes characteristic of ESCs. In this study, we confirmed and extended this observation, demonstrating that Cardiopoietic AF cell samples, such as ESCs, can give rise to EBs with cardiogenic potential, as evidenced by the significant increase in both Nkx2.5 expression and nuclear translocation. However, this method, which is generally used for the cardiac differentiation of ESCs and iPS cells, does not seem to be as efficient in generating CMs from AF cells because only approximately 30% of the differentiated progeny expressed the “late” cardiac marker α-MHC.

This finding is unsurprising because, although EBs are widely considered an optimal starting point for in vitro lineage-specific differentiation, the EB-mediated differentiation protocol has some important limitations. The efficiency, indeed, is dependent on EB size because larger EBs tend to differentiate toward mesoderm and endoderm, while smaller EBs direct their differentiation toward ectoderm: the lack of uniformity in EB size, resulting in nonhomogeneous and asynchronous differentiation of the residing cells hampers their effective employment in regenerative medicine. Moreover, we observed that in our model, the EB cells often presented condensed nuclei. This hallmark of apoptosis is probably due to the fact that cells within the aggregates suffer from limitations in the diffusion of nutrients and gas in the static culture environment. Laflamme et al. have already shown that cardiac differentiation from ES cells was more efficient in suspension and monolayer cultures than in EB-based methods. Because Cardiopoietic AF cells exhibit some aspects of ES cells, we tried to drive the Cardiopoietic AF cells toward the cardiac lineage using a directed differentiation approach in monolayers.

Most of the experiments on the differentiation potential of hAF cells reported in the literature have been carried out by isolating CD117+ cells from the initial heterogeneous population. Data on the surface markers of AF cells are not consistent among reports from different groups, and the results for the expression of c-kit/CD117...
in AF cells are mixed: some research demonstrated positive gene expression by PCR, but flow cytometry results were negative or only slightly positive\textsuperscript{21,31–33}. Moreover, considering that when detected, CD117\textsuperscript{+} cells represent only approximately 1–5% of AF cells, whereas the percentage of cells expressing pluripotent markers such as Oct4 or SSEA4 can be sensibly higher, the preferential selection of the c-kit\textsuperscript{+} subpopulation might be too restrictive to determine the possible loss of cells at the top of the stem hierarchy with high differentiation potential. Thus, it is still unclear whether sorting for CD117 expression is necessary or appropriate. A recent study reported that the unsorted population was more efficiently differentiated toward a neuronal lineage, whereas the c-kit-sorted population was better specified toward adipogenic, osteogenic, and chondrogenic lineages\textsuperscript{34}. These findings indicate that further research is needed to determine the appropriate isolation and culture procedures for the diverse differentiative endpoints. In any case, because the cells contained in AF are a heterogeneous mixture of many cell types, the analysis of undifferentiated AF cell samples is necessary to characterize the starting populations in differentiation experiments. Our data indicate that a subset of AF cell samples expressing pluripotent and multipotent stem markers - the Cardiopoietic AF cell samples - can differentiate into CM-like cells that, as discussed below, recapitulate some functional aspects of iPS- and ESC-derived CMs. This possibility to develop in vitro cardiogenic potential without resorting to any immunoselective method is pivotal: the absence of the use of xenogenic antibodies is indeed crucial in advancing cell therapy applications\textsuperscript{35}.

As reviewed by Petsche Connel\textsuperscript{22}, other groups have also reported that AF cells could be guided toward cardiac differentiation: rat or human c-kit\textsuperscript{+}–selected cells may acquire a CM phenotype when co-cultured with rat neonatal CMs, and functional communications develop among the cells of the co-culture\textsuperscript{14,17}. However, this differentiation process occurs with a very low yield and presents limits deriving from a xenogenic co-culture system\textsuperscript{36}. Other evidence suggests that the modulation of WNT\textsuperscript{15} signaling or exposure to 5-Aza\textsuperscript{14,15} may induce a CM phenotype in unselected AF cells, but these protocols were also characterized by low differentiation efficiency, and organized sarcomeric structures and spontaneous contraction were not detected. This partial differentiation is probably because modulation of WNT signaling or the application of demethylating agents are not able, alone, to fully commit hAF cells to a cardiac lineage\textsuperscript{14,15,19}. Yang and colleagues\textsuperscript{37} demonstrated that stage-specific addition of morphogenic and growth factors such as activin A, BMP4, FGF and VEGF led to the gradual transition of ES cells to mesoderm, eventually to form cardiovascular progenitors. Adapting this protocol, we obtained cells expressing several cardiac-specific markers from unselected Cardiopoietic AF.

**Figure 5.** Detection of the atrial marker MYL7 and of the ventricle-specific nuclear factor IRX4 in Cardiopoietic AF cells and in CM-like cells obtained after 15 days of differentiation. (a) Flow cytometry and (b) Western blot for MYL7 and IRX4 in Cardiopoietic AF cells and CMs. In Western Blot human heart and fibroblast lysates were used as controls. In the histogram of the cytometric analysis, the gray line represents the isotype control, the blue line represents Cardiopoietic AF cells and the red line represents CMs. (c) Merged immunofluorescent staining for MYL7 (green) and IRX4 (red) and nuclei (blue) in Cardiopoietic AF cells (left panel) and in CMs (right panel). Red arrows indicate the nuclear localization of IRX4 in the differentiated cells. Scale bar: 10 μm. Data are representative of seven independent experiments.
During the first phases of differentiation, we detected the upregulation and nuclear translocation of the cardiac nuclear factors GATA4 and Nkx2.5, which probably triggered the synthesis of “late” cardiac markers, such as specific structural and functional proteins. Moreover, Cardiopoietic AF cell-derived CM-like cells changed their aspect, developing an oblong/cylindrical morphology that recalled the shape and size of mature CMs. Our protocol results in the production of both atrial and ventricular myocytes, as testified by the expression of MYL7 and IRX4, two well-known cardiac-specific differentiation markers.

To contribute to cardiac function, newly generated CMs should be not only fully differentiated but also electrically integrated within the surrounding native cardiac tissue. Following the differentiation protocol, we observed upregulation of Cx43, localized at the cytoplasmic and membrane levels. Cx43 is a dominant connexin expressed in cardiovascular tissue and is a key component of gap junctions. One of the shortcomings of current patch materials for congenital heart defect repair is that they are non-conductive, which leads to an increased risk of arrhythmias and sudden cardiac death. The observation that upon differentiation, Cx43 also localized in the cell membrane indicates the possible initial formation of gap junctions. Although an electrical connection with neighboring cardiac cells will not be sufficient to avoid cardiac arrhythmias if the cells are not able to propagate the action potential at the same speed as the surrounding cells, this finding is a pivotal step in the maturation process.

Voltage gate ion channels are critical for all aspects of cardiac function, including rhythmicity and contractility. In the heart, prominent voltage-gated ion channels include sodium, potassium and calcium channels. We found that Cardiopoietic AF derived CM-like cells also slightly expressed Nav1.5 that is involved in the initiation and conduction of action potentials, the “delayed rectifier” KCNQ1 which is required for repolarization phase of the cardiac action potential, and the inward-rectifier potassium ion channel Kir2.1 that contributes to repolarization and to the setting of the resting membrane potential.

CMs are characterized by transient increases in intracellular Ca$^{2+}$ concentration, which are responsible for activating contraction. When an action potential depolarizes the cell membrane, voltage-gated Ca$^{2+}$ channels (L-type calcium channels) are activated, and the resulting Ca$^{2+}$ influx activates RyRs on the sarcoplasmic reticulum membrane, which causes more Ca$^{2+}$ to be released into the cytosol. This process, also called Ca$^{2+}$-induced Ca$^{2+}$ release, involves numerous ion channels, transporters and regulatory enzymes. In Cardiopoietic AF cell-derived CM-like cells, we found an increase in L-type calcium channel (CACNA1) expression. These channels appeared localized in both the cytoplasmic compartment and at the membrane level. Additionally, SERCA2 increased its expression in differentiated cells, depicting reticular structures that resembled the sarcoplasmic reticulum. Moreover, we found that approximately one-quarter of Cardiopoietic AF cell-derived CM-like cells expressed RyRs. These data are in accordance with our functional analyses, in which the presence of spontaneous calcium oscillations and responsiveness to a depolarizing agent were evident, although at different amplitudes of calcium transients. We also demonstrated that 20% of cells were caffeine responsive, namely, cells in which RyRs are capable of loading and unloading Ca$^{2+}$. This is indicative of the fact that we obtained CM-like cells with different...
levels of maturity, some of which displayed features characteristic of cardiac excitation-contraction with efficient Ca\(^{2+}\)-induced Ca\(^{2+}\) release. The finding of different levels of maturity is unsurprising: also in hES cell-derived CMs, only few cells are caffeine responsive and a great variability in RyR expression is observed, moreover representing only a small fraction (0.1%) of the adult level.\(^{43}\) In addition, when compared to adult CMs, hES cell-derived CMs exhibited smaller whole-cell peak amplitudes and slower upstroke and decay in calcium transients in response to caffeine.\(^{42}\) Finally, data from hiPS cell-derived CMs indicate the presence of spontaneous calcium transients associated with immature calcium-handling properties.\(^{44}\)

Isoproterenol, a \(\beta\)-adrenergic receptor agonist, is known to activate many intracellular targets involved in the control of excitation–contraction coupling and Ca\(^{2+}\)-induced Ca\(^{2+}\) release. Evidence that Cardiopoietic AF cell-derived CM-like cells are functionally immature was also revealed by results from intracellular calcium measurements in the presence of isoproterenol. Indeed, we observed that in approximately 35% of the cells, L-type Ca\(^{2+}\) channels responded to a depolarizing agent such as KCl, one-third of which (approximately 10% of the total population) were also responsive to isoproterenol. This observation is in accordance with previous results showing the same immature functional phenotype in hES and hiPS cells, in which the inotropic response appeared to be not affected by isoproterenol.\(^{45}\)

Recently, Jiang et al.\(^{45}\) showed that hAFs can be reprogrammed and subsequently used to generate functional CMs with robust and highly organized myofilament structures. In this study, we demonstrated that if the hAFs present the cardiopoietic phenotype (high expression of OCT4, SSEA4, CD90), it is possible to obtain CM-like cells that recapitulate the iPS- or cell-derived CM phenotype with a time- and cost-saving method that avoids cell reprogramming and all the risks related to iPS cell utilization.\(^{11}\)

In conclusion, the data presented herein suggest that unselected Cardiopoietic AF might be induced to differentiate into cells that express several cardiac-specific proteins and recapitulate some electrophysiological features of ES or iPS-cell-derived CMs, showing beating foci, albeit rare. Remaining challenges include the promotion of the maturation of these cells by improving their functional organization and electric properties. Addressing these challenges may require novel culture methods that better resemble the in vivo niche, and more attention must be paid to paracrine signaling and the cellular milieu. Despite these limitations, Cardiopoietic AF cells demonstrate potential as a tool to enhance basic biological understanding, to improve in vitro drug screening, and thus, to create new therapeutic options.

**Methods**

AF samples were obtained from 15 women undergoing amniocentesis for prenatal diagnosis at 16–17 weeks of pregnancy after written informed consent, in accordance with the Declaration of Helsinki. All samples had normal diploid male karyotypes, as evidenced by cytogenetic investigation. The mean (±SD) maternal age at amniocentesis was 37.9 ± 2.6 years (Table 1 and Supplemental Fig. 1). The study was approved by the ethics committee of the “G. d’Annunzio” University of Chieti-Pescara, ASL Lanciano-Chieti-Vasto, Italy and all experiments were performed in accordance with relevant guidelines and regulations.

**Isolation and culture of hAF cells.** hAF cells, isolated as previously described\(^{16}\), were cultured in Iscove’s modified Dulbecco’s medium (IMDM, Lonza Group Ltd, Basel, CH) supplemented with 20% fetal bovine serum (FBS, GE Healthcare HyClone Defined Fetal Bovine Serum, Buckinghamshire, UK), 100 U/mL penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, (all Sigma-Aldrich, Saint Louis, USA) and 5 ng/ml basic fibroblast growth factor (bFGF, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and incubated at 37°C with 5% humidified CO\(_2\).

**EB generation.** EBs were generated with the hanging drop method, as previously described.\(^{16}\) Briefly, hAF cells (6–8 passage) were harvested, and 25 μl drops of cellular suspension (1–10 × 10\(^4\) cells/ml) were cultured in IMDM supplemented with 15% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 10 μM 5-azadeoxycytidine (5-Aza) and 50 μg/ml ascorbic acid (all Sigma-Aldrich) in Falcon 100 mm × 15 mm Not TC-Treated Bacteriological Petri Dish (Corning, Flintshire, UK). After 6 days in suspension, the aggregates were transferred onto gelatin-coated tissue culture plates and grown for 10 days in the same medium.

**Culture in monolayer and cardiac differentiation.** hAFs were seeded onto Matrigel (Corning, Flintshire, UK)-coated plates and cultured as described above. When 80–90% confluence was reached, the medium was changed to RPMI 1640 (Life Technologies) supplemented with B-27 minus insulin (GIBCO, Thermo Fisher Scientific), 50 μg/mL ascorbic acid, 10/N 5-Aza, and differentiation was induced by exposure for 24 hr to activin A (30 ng/ml, R&D Systems) and BMP4 (25 ng/ml, R&D Systems), followed by a 72 hr treatment with VEGF (10 ng/mL, R&D Systems). Cells were analyzed after 15 days of differentiation.

**Flow cytometry and imaging flow cytometry.** For flow cytometry and imaging flow cytometry, cells were treated with the FIX & PERM® Kit (Thermo Fisher Scientific) and then incubated for 1 hr at RT with anti-Gata4 (1:50; Abcam), anti-Nkx2.5 (1:50; R&D Systems), anti-α-myosin heavy chain (α-MHC; 1:100; Abcam), anti-CD90 (1:50; BD), anti-cardiac Troponin T (cTnT, 1:100; Abcam), anti-α-sarcomeric actin (α-SA; 1:100; Abcam), anti-connexin 43 (Cx43; 1:100; Santa Cruz Biotechnology), anti-Sarcolemmal Ca\(^{2+}\) channel (CACNA1C, 1:100; Abcam), anti-Sarcoendoplasmic Reticulum Ca\(^{2+}\) ATPase protein (Serca2, 1:100; Invitrogen, Thermo Fisher Scientific), anti-Myl7 (1:100; Invitrogen), anti-IRX4 (1:100; Santa Cruz Biotechnology) or anti-Ryanodine receptor (RyR, 1:200 ThermoScientific, Rockford, Illinois, U.S.A.), followed by incubation with the appropriate secondary antibody conjugated with Alexa Fluor 488, PE-Alexa Fluor 647 or PE-Cy7 (1:200; Invitrogen, Thermo Fisher Scientific), as previously reported. Cells incubated with isotypes (all from BD) were used as negative controls.
For imaging flow cytometry, samples were examined by an ImageStream IS100 (Amnis, Merck-Millipore) multispectral imaging flow cytometer using a 488 nm solid state laser (50 mW) and Inspire software (v 4.1.434.0). Nuclei were counterstained with Syto16. Data were analyzed using IDEAS software v. 5.0 (Amnis, Merck-Millipore).

Cytometric analysis was performed with a Cytoflex cytometer (Beckman Coulter), and data were analyzed with FlowJo (TreeStar, Ashland, OR) or CytExpert Acquisition and Analysis Software.

**Immunoblot analysis.** For the immunoblot analysis, cells were lysed in RIPA homogenization buffer, electrophoresed in SDS–PAGE gradient 4–12% and transferred onto membranes that were then hybridized with anti- cTnT (1:500), anti-α-MHC (1:500), anti-α-SA (1:200), anti-Cx43 (1:200), anti-CACNA1C (1:1000), anti-SERCA2 (1:1000), anti-MYl7 (1:1000), anti-IRX4 (1:100), anti-β3, or anti-βα adrenoceptor (β3, or βα, AR, 1:100, Santa Cruz Technologies), anti-Nav1.5 (1:1000, Abcam), anti-KCNQ1 (1:500 ThermoFisher), anti-Kir2.1 (1:200 R&D System) or anti-G6PDH antibodies (1:1000; Santa Cruz Technologies), followed by the appropriate HRP-conjugated secondary antibodies (1:1000; Santa Cruz Technologies), as previously reported. Protein expression was detected with an enhanced chemiluminescence kit (Amersham, Little Chalfont, UK) and quantified by densitometry with ImageJ Software (Supplemental Fig. S2). Human heart extract and foreskin fibroblast cell lysates (Santa Cruz Technologies) were used as positive and negative controls, respectively.

**Immunofluorescence staining and microscopy.** Cells fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 were incubated with anti-GATA4 (1:50), anti-Nkx2.5 (1:50), anti-cTnT (1:100), anti-α-MHC (1:100), anti-α-SA (1:100), anti-Cx43 (1:100), anti-CACNA1C (1:100), anti-SERCA2 (1:100), anti-MYl7 (1:100), or anti-IRX4 (1:100), followed by the appropriate secondary antibody conjugated with Alexa Fluor 488 or PE (1:200), as previously reported. Nuclei were counterstained with DAPI. Samples treated only anti-MYL7 (1:100), or anti-IRX4 (1:100), followed by the appropriate secondary antibody conjugated with Alexa Fluor 488 or PE (1:200), as previously reported. Nuclei were counterstained with DAPI. Samples treated only with the secondary antibody were used as controls. Images were acquired with an Axio Vert A1 microscope or a Zeiss LSM 7 MP multiphoton microscope (Carl Zeiss, Jena, Germany) equipped with an Axio-Examiner. Z1 upright microscope. The two-photon excitation was obtained using a Ti:Sapphire Laser Coheren Camaleon Vision II in locked mode (Coherent Inc. Santa Clara, CA). Excitations were fixed at 730 nm or 980 nm and 1087 nm for DAPI, FITC and PE, respectively. Fluorescence emission was collected using an NDD detector set in which 2 mM Ca2+ was used as the mean photostimulated signal in a selected cell area, as f/f0, where f is the fluorescence intensity of a single loaded cell acquired during a time lapse, and f0 is the mean fluorescence intensity of the same cell calculated from images acquired during the first 5 s.

**Statistical analysis.** All quantitative data are presented as the mean ± SD. Statistical comparison was performed using one-way analysis of variance (ANOVA) and Student’s t-test. The level of significance was set at P < 0.05.

**Statement.** All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

**References**

1. WHO | Cardiovascular diseases (CVDs) http://www.who.int/mediacentre/factsheets/fs317/en/
2. Benjamin, E. J. et al. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. *Circulation* 135, e146–e603 (2017).
3. Di Mauro, M. et al. ACE and AGTR1 polymorphisms and left ventricular hypertrophy in endurance athletes. *Med Sci Sports Exerc.* 42, 915–21 (2010).
4. Goldberg, S., Freibee, J. C. & Lacher, I. Chronic stress impacts the cardiovascular system: animal models and clinical outcomes. *Am J Physiol Heart Circ Physiol* 308, H1476–98 (2015).
5. D’Amico, M. A. et al. IL-6 Activates PI3K and PKCζ; Signaling and Determines Cardiac Differentiation in Rat Embryonic H9c2 Cells. *J Cell Physiol* 231, 576–586 (2016).
6. Denas, O. et al. Genome-wide comparative analysis reveals human-mouse regulatory landscape and evolution. *BMC Genomics* 16, 67 (2015).
7. Kahn, P. C. et al. Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. *PLoS One* 6, e26389 (2011).
8. Xu, C., Police, S., Rao, N. & Carpenter, M. K. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. *Circ Res* 91, 501–508 (2002).
9. Zhao, P. et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. *Transplantation* 79, 528–535 (2005).
10. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).

11. Di Baldassarre, A., Cimetta, E., Bollini, S., Gaggi, G. & Ghinassi, B. Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications. Cells 7, E48 (2018).

12. Izicufo, P. et al. Effects of ACE 1/D polymorphism and aerobic training on the immune-endocrine network and cardiovascular parameters of postmenopausal women. J Clin Endocrinol Metab 98, 4187–94 (2013).

13. Loukogeorgakis, S. P. & De Coppi, P. Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications. Stem Cells 35(7), 1663–1673 (2017).

14. Guan, X., Delo, D. M., Atala, A. & Sokol, S. In Vitro Cardiomyogenic Potential of Human Amniotic Fluid Stem Cells. J Tissue Eng Regen Med 5, 220–228 (2011).

15. Petsche Connell, J., Ruano, R. & Jacot, J. G. Amniotic fluid-derived stem cells demonstrate limited cardiac differentiation following small molecule-based modulation of Wnt signaling pathway. Biomed Mater 10, 034103 (2015).

16. Antonucci, I. et al. Human second trimester amniotic fluid cells are able to create embryoid body-like structures in vitro and to show typical expression profiles of embryonic and primordial germ cells. Cell Transplantation 23, 1501–1515 (2014).

17. Bollini, S. et al. In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev 7, 364–380 (2011).

18. Cananzi, M. & De Coppi, P. CD117(+) amniotic fluid stem cells: state of the art and future perspectives. Organogenesis 8, 77–88 (2012).

19. Moschidou, D. et al. Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Ther 20, 1953–1967 (2012).

20. Gao, Y. et al. Amniotic fluid-derived stem cells demonstrated cardiogenic potential in indirect co-culture with human cardiac cells. Ann Biomed Eng 42, 2490–500 (2014).

21. Lee, W. Y. et al. Enhancement of cell retention and functional benefits in myocardial infarction using human amniotic-fluid-stem-cell bodies enriched with endogenous ECM. Biomaterials. 32, 5558 (2011).

22. Petsche Connell, J., Camci-Unal, G., Khademhosseini, A. & Jacot, J. G. Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications. Tissue Eng Part B Rev 19, 368–379 (2013).

23. Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA 109, E1848–857 (2012).

24. Shiba, Y. et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322–325 (2012).

25. Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25, 1015–24 (2007).

26. Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes. Nat Methods 11, 85–60 (2014).

27. Yoshida, Y. & Yamanaka, S. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res 120, 1958–1968 (2017).

28. Hentze, H. et al. Teratoma formation by human embryonic stem cell: evaluation of essential parameters for future safety studies. Stem Cell Res 2, 198–210 (2009).

29. Mummery, C. L. et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111, 344–358 (2012).

30. Xu, F. et al. Embryonic stem cell bioprinting for uniform and controlled size embryoid body formation. Biomicrofluidics 5, 22207 (2011).

31. Siegel, N., Valli, A., Fuchs, C., Rosner, M. & Hengstschläger, M. Induction of mesenchymal/epithelial marker expression in human amniotic fluid stem cells. Reprod Biomed Online 19, 838 (2009).

32. Yeh, Y. C. et al. Cellular cardiomyoblasts with human amniotic fluid stem cells: In vitro and in vivo studies. Tissue Eng Part A 16, 1925 (2010).

33. Benavides, O. M., Petsche, J. J., Moise, K. J., Johnson, A. & Jacot, J. Evaluation of endothelial cells differentiated from amniotic fluid-derived stem cells. Tissue Eng Part A 18, 1123 (2012).

34. Arnhold, S. et al. Amniotic-fluid stem cells: Growth dynamics and differentiation potential after a cd-117-based selection procedure. Stem Cells Int. 2011, 715341 (2011).

35. Vanmuri, M. C. et al. Derivation of human embryonic stem cells in xenofree conditions. Methods Mol Biol 407, 1–10 (2007).

36. Smit, N. W. et al. Human Cardiomyocyte Progenitor Cells in Co-culture with Rat Cardiomyocytes Form a Pro-arrhythmic Substrate: Evidence for Two Different Arrhythmogenic Mechanisms. Front Physiol. 8, 797 (2017).

37. Yang, L. et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453, 524–8 (2008).

38. Ban, K. et al. Non-genetic Purification of Ventricular Cardiomyocytes from Differentiating Embryonic Stem Cells through Molecular Beacons Targeting IRX-4. Stem Cell Reports 5, 1239–1249 (2015).

39. Pok, S. & Jacot, J. G. Biomaterials advances in patches for congenital heart defect repair. J Cardiovasc Transl Res 4, 646–654 (2011).

40. Liu, J., Pu, J. D., Sui, C. W. & Li, R. A. Functional sarcomplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. Stem Cells 25, 3038–3044 (2007).

41. Satin, J. et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 26, 1961–1972 (2008).

42. Dolnikov, K. et al. Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcomplasmic reticulum in the contraction. Stem Cells 24, 236–245 (2006).

43. Lee, Y. K. et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Rev 7, 976–986 (2011).

44. Pillekkamp, F. et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev 21, 2111–2121 (2012).

45. Jiang, G. et al. Human Cardiomyocytes Prior to Birth by Integration-Free Reprogramming of Amniotic Fluid Cells. Stem Cells Transl Med 5, 1595–1606 (2016).

46. Martelli, F. et al. Thrombopoietin inhibits murine mast cell differentiation. Stem Cells 26, 912–919 (2008).

47. Di Fonzo, A. et al. Novel evidence of ghrelin and growth hormone segretagogue receptor expression by human ocular tissues. Regul Pept 190–191, 18–24 (2014).

Acknowledgements

This work was supported by the Italian Ministry of Education, University and Research (Ministero dell’Istruzione, dell’Università e della Ricerca-MIUR), grant number SIR2014-RBS1140GLQ.

Author Contributions

A.D.B. designed and wrote the manuscript; M.A.D. collected and analyzed the data; P.I. analyzed the data; G.G. made the experiments; S.G. collected and analyzed the data; M.A.M. analyzed the data; I.A. provided study material; B.C.: wrote the manuscript; D.S. provided the study material; L.S. analyzed the data; B.G. designed and wrote the manuscript. All authors reviewed the manuscript.
Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-30537-z.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018